Astellas Collaborates with Vir to Develop Its Experimental Prostate Cancer Drug

2019-12-03T000000Z_2056628389_RC2HND9W9MUW_RTRMADP_3_AUDENTES-M-A-ASTELLAS-PHARMA
Feb 23 (Reuters) – Japan’s Astellas and Vir Biotechnology said on Monday they will together develop and commercialize the U.S. drug developer’s prostate cancer experimental drug.

New contents